DexCom, Inc. reported first-quarter adjusted earnings of 32 cents per share, significantly missing expectations of 50 cents, while revenue rose by 25% year-over-year to $628.8 million, surpassing Wall Street forecasts. The company maintained its 2022 revenue guidance of $2.82 to $2.94 billion, anticipating a growth of 15-20% from the previous year. Despite this positive revenue momentum, DexCom's stock has dropped roughly 23.1% since the start of the year, with analysts expressing mixed views on its future performance.
“DexCom, Inc. · reported · adjusted earnings · 32 cents per share”
“DexCom, Inc. · expects · revenue · in the range of $2.82 - 2.94 billion”
“DexCom, Inc. · reported · first-quarter 2022 adjusted earnings per share (EPS) · 32 cents”
“DexCom, Inc. · missed · the Zacks Consensus Estimate · 50 cents”
“DexCom, Inc. · declined · the bottom line · 3%”
“DexCom · generated · an adjusted gross margin · 63.3%”
“DexCom exited the first quarter · with · cash, cash equivalents and marketable securities · $2.69 billion”
“DexCom has decided to reiterate 2022 guidance · for revenues · $2.82-$2.94 billion”
“DexCom expects revenues · to reflect growth · from the previous year · 15-20%”
“DexCom exited the first quarter 2022 · on a mixed note · wherein earnings missed but revenues beat”
“DexCom ended the quarter · with · new patient additions”
“Currently, DexCom has a Zacks Rank · is · #3 (Hold)”
